Mubadala Bio Launches To Transform Life Sciences And Healthcare In The UAE

Mubadala Investment Company, based in Abu Dhabi, has introduced Mubadala Bio, a life sciences firm. This initiative aims to enhance the UAE's life sciences sector and improve health outcomes globally. Mubadala Bio is part of a strategic effort to boost healthcare resilience, ensure drug security, and expand access to essential medical products while supporting the UAE's economic diversification.

The company's extensive portfolio includes ten facilities across Asia, Africa, and Europe, with six located in the Emirates. These sites serve over 100 countries and have a combined manufacturing capacity exceeding 2.5 billion tablets and capsules annually. Additionally, they produce 120 million IVs and injectables each year within a total area of 110,000 square metres.

Mubadala Bio concentrates on addressing critical health needs worldwide by offering comprehensive care solutions. Their approach covers prevention, diagnosis, treatment, ongoing support, and complementary medicine. This strategy is designed to provide integrated disease solutions that span the entire continuum of care.

By establishing long-term partnerships with global industry leaders and top academic institutions, Mubadala Bio aims to accelerate biopharma innovation and local manufacturing. This collaboration helps cultivate world-class talent and drive rapid advancements in the field.

Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform, highlighted the significance of launching Mubadala Bio. He stated that it represents a transformative step towards enhancing national drug security and fostering innovation in life sciences. "This positions Mubadala at the forefront of the industry," he said.

Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala's UAE Investments Platform, emphasised that this launch is a significant milestone for the UAE's leadership in life sciences. The focus will be on strengthening local capabilities in development, manufacturing, logistics, and distribution throughout the supply chain.

Supporting UAE’s Centennial Vision

Mubadala Bio aims to align with the UAE’s Centennial 2071 vision by focusing on integrated biopharma and pharma logistics. As part of its launch activities, it will participate in "Make it in the Emirates 2025," showcasing the UAE’s achievements in building a competitive life sciences industry.

This event will highlight the country's success as an innovation hub for local manufacturing. It underscores Mubadala Bio's commitment to reinforcing its position as a leader in advancing health solutions globally while contributing to economic growth.

With inputs from WAM